Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/infdis/jiaa579 http://scihub22266oqcxt.onion/10.1093/infdis/jiaa579 32906151!7499676!32906151     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Infect+Dis 2020 ; 222 (12): 1955-1959 Nephropedia Template TP {{tp|p=32906151|t=2020. High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts |pdf=|usr=}}{{32906151}} gab.com Text High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts JO: J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32906151 #FOAvip SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM+IgG+, 9.0% IgM+IgG-, and 5.0% IgM-IgG+). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM+IgG-. These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection. Twit Text FOAVip High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts ????J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32906151 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32906151 #FOAvip English Wikipedia <ref>{{Cite pmid|32906151}}</ref> High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts #MMPMID32906151 Naranbhai V; Chang CC; Beltran WFG; Miller TE; Astudillo MG; Villalba JA; Yang D; Gelfand J; Bernstein BE; Feldman J; Hauser BM; Caradonna TM; Alter G; Murali MR; Jasrasaria R; Quinlan J; Xerras DC; Betancourt JR; Louis DN; Schmidt AG; Lennerz J; Poznansky MC; Iafrate AJ J Infect Dis 2020[Nov]; 222 (12): 1955-1959 PMID32906151show ga SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM+IgG+, 9.0% IgM+IgG-, and 5.0% IgM-IgG+). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM+IgG-. These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection. |*Point-of-Care Systems[MESH] |Adult[MESH] |Antibodies, Viral/*blood[MESH] |Antibody Specificity[MESH] |COVID-19/*diagnosis/epidemiology/virology[MESH] |Enzyme-Linked Immunosorbent Assay[MESH] |Female[MESH] |Humans[MESH] |Immunoassay[MESH] |Immunoglobulin G/blood[MESH] |Immunoglobulin M/blood[MESH] |Male[MESH] |Massachusetts/epidemiology[MESH] |Middle Aged[MESH] |Multivariate Analysis[MESH] |Regression Analysis[MESH]High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachu(epmc).pdf DeepDyve Pubget Overpricing